Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study

Not Applicable

Completed

• Conditions: Health Condition 1: null- Chronic plaque psorisis

• Registration Number: CTRI/2017/12/010891
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2013-03-31
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 43

Inclusion Criteria

1.Patients having >10% of body surface area involved by psoriasis and no psoriatic arthritis.

2.Patients having moderate-to-severe chronic plaque psoriasis (defined by a score of at least 6 on the Psoriasis Area-and-Severity Index (PASI).

3.Patients not on any form of systemic antipsoriatic treatment for at least 4 weeks and/or topical treatment for at least 2 weeks prior to the initiation of therapy.

Exclusion Criteria

1.Patients less than 18 years of age.

2.Pregnant and / or lactating females.

3.Patients noncompliant with an effective regimen of contraception.

4.Patients having hepatic or renal impairment, deranged lipid profile, hematologic impairment, any acute infection requiring antimicrobial therapy, uncontrolled hypertension or diabetes mellitus, with BMI >30 or known psychiatric illness.

5.Patients having a history of cancer, including skin cancer or hematologic, cerebral or pulmonary neoplasia.

6.Patients who were alcoholic or had a long history of alcohol intake.

Study & Design

• Study Type: Interventional
• Study Design: Not specified